HomeNewsTrendsHealthReliance's Strand Life Sciences develops prenatal genomic diagnostics portfolio

Reliance's Strand Life Sciences develops prenatal genomic diagnostics portfolio

These advancements are customised to meet the unique requirements of the Indian population and provide unmatched precision, economy, and efficiency, according to a release by the company.

April 24, 2024 / 07:57 IST
Story continues below Advertisement
Prenatal diagnosis can help detect Down Syndrome and other fetal abnormalities.
Prenatal diagnosis can help detect Down Syndrome and other fetal abnormalities.

Reliance Industries Ltd’s life sciences unit has introduced its portfolio of prenatal diagnostics and screenings, including MaatriSeq for non-invasive prenatal screening and CNSeq for diagnosing aneuploidies, a genetic disorder.

These advancements are customised to meet the requirements of the Indian population and provide precision, economy, and efficiency, according to a release by Strand Life Sciences.

Story continues below Advertisement

“Strand is at the forefront of advanced genomic solutions and continues to redefine standards in genetic diagnostics. With these innovations, Strand wants to contribute to the efforts of the Indian government to reduce the burden of rare diseases in India,” said Ramesh Hariharan, CEO and co-founder of Strand Life Sciences.

CNSeq incorporates the most recent sequencing technology in prenatal tests. It outperforms conventional cytogenetic and molecular approaches in identifying copy number variations (CNVs) with precision because of its patented software.